Northstar Response®
Pan-Cancer Liquid Biopsy for Treatment Monitoring
CommercialActive
Key Facts
Indication
Pan-Cancer Liquid Biopsy for Treatment Monitoring
Phase
Commercial
Status
Active
Company
About BillionToOne
BillionToOne is a commercial-stage precision diagnostics company with a mission to remove the fear of the unknown by providing accurate, fast, and accessible molecular diagnostics. The company has achieved significant milestones, including a successful November 2025 IPO and the commercial launch of its UNITY prenatal and Northstar oncology liquid biopsy suites, which are built on its proprietary single-molecule NGS platform. Its strategy is to dominate high-growth segments in prenatal screening and oncology by leveraging its unique ability to quantify sparse DNA fragments with single-molecule precision, thereby addressing critical unmet needs in early disease detection and monitoring.
View full company profile